Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Subscribe To Our Newsletter & Stay Updated
